May 29, 2020
Number of shares and votes in Oncopeptides
May 28, 2020
Oncopeptides Reinitiates Patient Enrollment to the Melflufen Clinical Program Following a Temporary Pause due to the COVID-19 Pandemic
May 26, 2020
Oncopeptides AB: Interim Report Q1 2020
May 22, 2020
Oncopeptides Completes Enrollment to the Pivotal Phase 3 Study OCEAN for Relapsed Refractory Multiple Myeloma - 450 Patients Included
May 14, 2020
Oncopeptides Announces New Clinical and Preclinical Melflufen Data at the Upcoming European Hematology Association Meeting
May 13, 2020
Oncopeptides Announces that Two Abstracts on Multiple Myeloma have been Accepted by the 2020 ASCO Annual Meeting
Apr 22, 2020
Annual General Meeting in Oncopeptides AB (publ)
Apr 02, 2020
Oncopeptides Strengthens its Corporate Communications Function by Appointing Rolf Gulliksen as Global Head of Corporate Communications
Mar 26, 2020
Oncopeptides Announces 26% Overall Response Rate of Melflufen in Triple-class Refractory Multiple Myeloma Patients From the Pivotal HORIZON Study
Mar 23, 2020
The Lancet Haematology Publishes Results From Oncopeptides' Multicenter, International Phase 1/2 Study (O-12-M1)
Mar 20, 2020
Oncopeptides Provides Update Regarding COVID-19 Impact on the Melflufen Clinical Program
Mar 02, 2020
Oncopeptides Strengthens its Organization by Appointing Karolina Vilval as General Counsel
Jan 24, 2020
Oncopeptides will Host a Webcast on Monday, January 27th at 11.00 (CET)
Jan 07, 2020
Oncopeptides Strengthens its Regulatory Function by Appointing Karin Eklund Vanderpol as Head of Regulatory Affairs
Dec 17, 2019
Bulletin From the Extraordinary General Meeting in Oncopeptides AB (publ)
Dec 07, 2019
Oncopeptides Presents Updated Efficacy and Safety Data from Pivotal Phase 2 HORIZON Study in Patients With RRMM at ASH Annual Meeting 2019
Dec 06, 2019
Oncopeptides Will Host a Webcast on Tuesday, December 10th at 13:00 (CET) to Provide an Update Regarding Data Presented at the ASH Annual Meeting
Dec 02, 2019
Oncopeptides Appoints Joseph Horvat as President North America
Nov 14, 2019
Extraordinary General Meeting in Oncopeptides AB (publ)
Nov 06, 2019
Oncopeptides to Highlight Data From Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019